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Prednisone and prednisolone bioavailability in renal transplant pa.
tients. Prednisone and prednisolone are drugs with the potential for
therapeutic inequivalence due to bioavailability problems. The objec-
tive of our study was to compare the systemic bioavailability of
prednisolone from oral prednisone and prednisolone. Nine kidney
transplant patients receiving prednisone (12.5 to 22.5 mg per day) were
administered, in a randomized fashion, the same dose of oral predni-
sone (Deltasone®), oral prednisolone (Deltacortef®) and intravenous
prednisolone (Hydeltrasol®). Prednisolone and prednisone levels were
measured using a specific high-pressure liquid chromatographic assay.
Since prednisolone exhibits dose-dependent pharmacokinetics because
of nonlinear plasma protein binding, bioavailability was determined
from unbound as well as total drug concentrations. Mean prednisolone
bioavailability from oral prednisone and oral prednisolone, compared to
the intravenous dose, was 84.5 17.8% and 95.5 17.6% using
unbound drug concentrations and 86.1 9.1% and 93.6 9.2%
determined from total drug concentrations. These differences were not
statistically significant. Furthermore, no significant differences were
observed between the two oral formulations in peak prednisolone
levels, time of peak levels or half-life using either total or unbound drug
concentrations, The results from our study indicate that both of the oral
preparations tested provide similar bioavailability of active predniso-
lone and the conversion of prednisone to prednisolone occurs rapidly.
Blodisponibilité de Ia prednisone et de Ia prednisolone chez des
transplantes renaux. La prednisone et la prednisolone sont des médica-
ments dont le potentiel thérapeutique peut différer en raison de prob-
lèmes de biodisponibilité. Le but de notre étude a eté de comparer La
biodisponibilité systémique de Ia prednisolone a partir de prednisone ou
de prednisolone données per os. Neuf transplantés rénaux recevant de
Ia prednisone (12,5 a 22,5 mg/jour) ont recu de facon randomisée la
méme dose de prednisone (Deltasone®) orale, de prednisolone (Delta-
cortef®) orale ou de prednisolone (Hydeltrasol®) intraveineuse. Les
concentrations de prednisolone et de prednisone ont eté déterminées
avec un dosage spécifique utilisant une chromatographie liquide a haute
pression. La prednisolone ayant une pharmacocinetique dose-depen-
dante en raison de Ia non linéarité de sa liaison aux protéines plasma-
tiques, sa biodisponibilité a été déterminée a partir de ses concentra-
tions plasmatiques totale et libre. La biodisponibilite moyenne de La
prednisolone a partir de prednisone ou de prednisolone orale, comparée
a l'administration intraveineuse était de 84,5 17,8% et 95,5 17,6% a
partirdes concentrations libres et de 86,1 9,1% et 93,6 9,2% a partir
des concentrations totales. Ces differences n'étaient pas significatives.
De plus, il n'y avait pas de differences significatives entre les 2
preparations orales en cc qui concerne les pics de concentrations de
prednisolone, l'heure de ces pics de concentrations ou Ia demi-vie,
qu'on utilise les concentrations totales ou libres. Les rCsultats de notre
étude indiquent que les deux preparations orales testées offrent une
biodisponibilite de prednisolone active identique, et que Ia transforma-
tion de prednisone en prednisolone se produit rapidement.
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Prednisone and prednisolone are synthetic glucocorticoid
compounds commonly used in the treatment of a wide variety
of disease states. Prednisone is assumed to be inactive and must
be converted to the bioactive moiety prednisolone, which
occurs via reduction of the 1 1-oxo group primarily by the liver
enzyme, 1 1-3-hydroxydehydrogenase. In the absence of signifi-
cant liver disease, the biotransformation of prednisone to
prednisolone is usually rapid and extensive [1, 2]. In healthy
subjects Rose, Yurchak, and Jusko [3] found the mean systemic
bioavailability of prednisolone from oral prednisone to range
from 85 to 99%. Some investigators have indicated that the
administration of equal doses of either drug to normal subjects
resulted in similar plasma prednisolone concentration-time pro-
files [4, 51. However, other studies have demonstrated signifi-
cantly higher peak prednisolone levels, larger areas under the
plasma prednisolone concentration-time curve and greater
prednisolone bioavailability following oral prednisolone com-
pared with equivalent oral doses of prednisone [6—9]. Further-
more, it has been shown that a significantly greater variation
exists in prednisolone bioavailability after oral prednisone
dosing than after oral prednisolone dosing [6]. It has been
suggested that if predictable plasma prednisolone concentra-
tions are to be achieved, prednisolone should be used [6]. Some
oral prednisone and prednisolone products may not be bio-
equivalent and drug substitution could result in important
changes in the level of active prednisolone available. Thus
formulation factors and possible differences in biotransforma-
tion determine the bioavailability of prednisolone from these
orally administered corticosteroids.
The objective of our study was to determine the systemic
bioavailability of prednisolone from a commonly used commer-
cial formulation of prednisone and of prednisolone in kidney
transplant patients. These patients are usually administered oral
prednisone for immunosuppression. Bioavailability was as-
sessed both in terms of total and unbound concentrations
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because the dose-dependent pharmacokinetics of prednisolone
are primarily due to concentration-dependent plasma protein
binding [3, 10—13].
Methods
Protocol. Nine clinically stable kidney transplant patients
(six males, three females) ranging in age from 25 to 56 years (34
10; mean SD) participated in our study, which was
approved by the Committee on Human Research, University of
California, San Francisco. Their weights ranged from 57 to 88
kg (72 11) and six patients (nos. 2, 3, 4, 6, 7, 8) were clinically
cushingoid. All patients were studied from 5 to 27 months
following cadaver renal transplantation and had good to satis-
factory kidney function with the serum creatinine ranging from
0.9 to 2.6 mg/dl (1.7 0.5). Tests of liver function and serum
albumin levels (range 4.1 to 4.6 g/dl) were in the normal range.
All patients were taking a single daily maintenance dose of
prednisone ranging from 12.5 to 22.5 mg. In addition, they were
receiving azathioprine and various other drugs such as methyl-
dopa, hydralazine, furosemide, propranolol, and vitamins.
Each patient was studied on three separate occasions in a
randomized crossover design. On one occasion they received
their usual oral dose (12.5 to 22.5 mg) of prednisone as
Deltasone® (The Upjohn Company, Kalamazoo, Michigan) and
on another the same oral dose of prednisolone as Deltacortef®
(The Upjohn Company). On the third occasion patients were
administered an equivalent intravenous bolus dose of predniso-
lone as prednisolone sodium phosphate, Hydeltrasol® (Merck,
Sharp and Dohme, West Point, Pennsylvania). Patients were
fasted from midnight prior to the study day and for 4 hr after the
dose the next morning. Venous blood samples, 10 ml each,
were obtained from a heparin lock in a peripheral arm vein
before the oral or intravenous doses and at 0.25, 0.5, 1, 2, 3, 4,
6, 8, 10, and 12 hr after the dose, Additional samples were
collected at 2.5, 5, and 10 mm following the intravenous dose.
Blood samples were collected in heparinized Vacutainer® blood
collection tubes (stoppers removed) and immediately centri-
fuged; the plasma was removed and then frozen at —70° C until
assayed.
Analytical methods and protein binding. Plasma concentra-
tions of prednisolone, prednisone, cortisol, and cortisone were
determined using a high-pressure liquid chromatographic assay
[141. This specific assay method allows the simultaneous mea-
surement of these glucocorticoid compounds. The measure-
ment limit for routine analysis is 5 ng/ml. The analytical
recovery for all compounds is greater than 75%; the intraday
variability is 1 to 3% (coefficient of variation) and the interday
variability 3 to 10% (coefficient of variation).
The plasma protein binding of prednisolone was determined
by equilibrium dialysis. Due to the nonlinear concentration-
dependent binding of prednisolone the protein binding of all
plasma samples from each patient were determined. Acrylic
plastic equilibrium dialysis cells (Technilab®) with a 1-mi maxi-
mum capacity per cavity were used. The membrane used was
Spectrapor® No. 2 (Spectrum Medical Industries, Queens, New
York) with a molecular weight cutoff of 12000 to 14000. One-
half ml of plasma is equilibrated against 0.5 ml of isotonic
Krebs-Ringer buffer (pH 7.4; 0.153 M) containing [6,7 (n)-3H]
prednisolone (9 ng/ml; specific activity 43 Ci/mmoles; 96 to 99%
radiochemical purity; Amersham, Arlington Heights, Illinois).
In addition, the purity of the radiolabeled prednisolone was
confirmed in our laboratory prior to use by thin-layer chroma-
tography and found to be 98% pure. The amount of labeled
prednisolone used was included in all calculations of protein
binding. Equilibrium was reached at 16 hr in a Dubnoff®
Metabolic Shaking Incubator, at a water temperature of 37° C.
One-tenth ml of dialyzed plasma and 0.1 ml of dialyzed buffer
were then transferred to individual glass scintillation vials to
which is added 10 ml Aquasol® (New England Nuclear, Boston,
Massachusetts). After being shaken, the vials were counted on
a Packard Liquid Scintillation Spectrometer (Model 3320). The
counts per minute of the plasma and buffer samples are convert-
ed to disintegrations per minute using the channels-ratio meth-
od of quench correction. Additional correction was made for
background counts. Less than 2% of the radioactivity was
bound to the dialysis membrane and/or cell surfaces. Plasma
samples containing prednisolone (387 to 6720 ng/ml) analyzed
after equilibrium dialysis by both radiochemical assay and
HPLC assay indicated similar results for the percent of the
prednisolone bound to plasma proteins [13]. The coefficient of
variation for paired observations was 6.1%. Thus the radiola-
beled compound did not give erroneous results after the equili-
bration period, and all subsequent protein binding studies were
carried out using radioactivity measurements. Prednisolone is
stable in the dialysis cells during the equilibration period.
Furthermore, the presence of heparin in plasma at both low (14
U/ml) and high (100 U/mI) concentrations does not alter the
protein binding of prednisolone compared to serum (containing
no heparin), over varying prednisolone concentrations up to
5000 ng/ml. Calculations of the bound and unbound drug
concentrations postdialysis were made with corrections for the
shifts of drug and volume changes occurring during the dialysis
procedure (Tozer, Gambertoglio, Furst, Avery, and Holford, to
be published). This correction is necessary in equilibrium
dialysis studies because of the increase in the plasma volume
side relative to buffer volume side postdialysis which causes a
decrease in plasma bound and unbound drug concentrations.
Furthermore, prednisolone concentrations on the plasma side
decrease due to diffusion from plasma into buffer during the
dialysis. Thus at equilibrium the concentration of total prednis-
olone in plasma is lower than that obtained from the patient and
measured by HPLC; and thus, the fraction unbound corre-
sponds to this lower total drug concentration. The concentra-
tions of unbound (Pa) and bound (Pbfld) drug postdialysis were
then calculated for each plasma sample.
Data analysis. (I) Protein binding: Prednisolone binding to
plasma protein is nonlinear and may be described by the
function [3, 15—18]:
Pbfld=(CAPl'PU)+(KDl+PU)+SPU Eq.l
where CAPI and KD1 are the binding capacity and dissociation
constant of a saturable binding site (transcortin), and S is the
ratio of capacity to dissociation constant (CAP2/KD2) of a
nonsaturated binding site (albumin). Once estimates of the
binding parameters, CAP1, KD1, and S for prednisolone are
obtained from each patient's study the unbound concentration
is derived from equation 2. That is:
=
(B + VB2 + 4 A KD1 A Eq. 2
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Fig. 1. Total plasma concentrations of prednisolone and prednisone
in patient 9 following the administration of 15 ,ng oral prednisone(• - - - - S) and 15 mg oral prednisolone (•
where P0 is total plasma concentration in vivo, B = (P0 —
CAP1 — A) and A = 1 + S. This equation relates the total
concentration of prednisolone measured in the patient (that is,
before equilibrium dialysis) to the concentration of unbound
drug in that same patient's sample. Protein binding parameters
were estimated using unweighted nonlinear least squares re-
gression [19].
(2) Pharmacokinetics: A two-compartment model was used
to describe plasma concentrations. Bolus input was used for
intravenous doses and zero-order absorption with lag time for
oral doses. Observed concentrations were weighted by the
reciprocal of the value squared. Half-life was calculated by
dividing 0.693 by the elimination rate constant. The area under
the plasma concentration time curve (AUC) was obtained using
the log-trapezoidal rule and the remaining AUC beyond the last
measured data point was estimated by dividing the predicted
value for the last data point by the terminal disposition rate
constant estimated from the pharmacokinetic model. The sys-
temic bioavailability of prednisolone from the oral prednisolone
doses was calculated from the ratio of the area under the curve
of prednisolone after the oral steroid dose to the area under the
curve from the intravenous prednisolone. Plasma clearance
(CL) and volume of distribution at steady-state (Vss) were
calculated using the two-compartment model parameter esti-
mates in the following expressions:
CL = V1
-
and Vss = V1 [(K21 + K12) ÷ (K21)]
Eqs. 3 and 4
Fig. 2. Total plasma prednisolone concentrations in patient 8 fol-
lowing the administration of 22.5 mg of intravenous prednisolone,(• •), oral prednisolone, (• •), and oral pred-
nisone (•
where V1 is the volume of the central compartment; a and 3 are
the initial and terminal disposition rate constants; and K12 and
K21 are the intercompartmental distribution rate constants.
Compartment-independent estimates of CL and Vss were cal-
culated using:
DoseCL = and Vss = [Dose (AUMC)] ÷ (AUC)2
Eqs. 5 and 6
where AUMC is the area under the first moment of the plasma
concentration-time curve using the log-trapezoidal rule [20, 21].
The pharmacokinetic parameters describing the disposition of
prednisolone based on total and free drug plasma concentra-
tions were estimated by non-linear least squares regression [22].
Prednisone half-life was estimated using log-linear regression
when at least four points on the terminal linear portion of the
plasma curve had been measured.
Statistical analysis. Statistical comparisons between pharma-
cokinetic parameters were made using Student's paired r test
and Wilcoxon's sign rank test for paired data on the PROPHET
computer system [23]. Both tests were applied to all compari-
sons and a statistically significant difference was defined as P <
0.05. Results are reported as mean SD.
Results
The bioavailability characteristics of oral prednisone and oral
prednisolone were made by comparing peak prednisolone con-
centrations, time of peak levels, half-life and bioavailability of
prednisolone compared to an intravenous dose of prednisolone.
Figure 1 shows total plasma prednisolone and prednisone
concentrations in patient 9 following oral prednisone and oral
prednisolone administration. After either oral steroid dose,
similar plasma concentrations of prednisolone and prednisone
were observed, demonstrating the rapid interconversion of the
two steroids. Prednisolone bioavailability was 81 and 88% from
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Table 1. Prednisolone bioavailability data from oral prednisone and oral prednisolonea
Total prednisolone concentration Unbound prednisolone concentration




















P P0 P P0 P P0 P P0 P P0 P P0 P P0
1 15 78 1.0 3.0 228 262 3.2 3.1 81.3 100.3 43 51 2.7 2.4 69.4 88.9
2 15 76 0.5 1.0 550 452 3.3 3.2 92.8 87.7 150 82 2.3 2.4 103.8 79.9
3 17.5 82 0.5 1.0 455 332 3.8 4.3 103.7 110.7 100 80 2.9 3.4 110.4 129.3
4 15 75 2.0 2.0 282 272 3.4 3.3 78.0 87.7 57 54 2.8 2.8 69.2 81.8
5 15 70 2.0 2.0 212 237 3.5 2.6 94.5 81.0 24 42 3.2 2.0 65.9 72.3
6 12.5 58 1.0 1.0 315 371 3.8 3.5 85.1 102.5 61 104 2.9 2.6 67.6 94.5
7 12.5 88 0.5 0.5 246 292 2.9 3.2 75.4 91.5 50 61 2.4 2.8 81.1 111.6
8 22.5 57 1.0 1.0 508 556 3.4 3.4 82.6 92.7 101 146 2.4 2.3 89.2 99.5
9 15 60 1.0 2.0 258 308 3.5 3.4 81.3 88.1 54 58 2.7 2.6 103.5 101.5
Mean 1.1 1.5 339 342 3.4 3.3 86.1 93.6 71 75 2.7 2.6 84.5 95.5
SD 0.6 0.8 129 103 0.3 0.5 9.1 9.2 39 33 0.3 0.4 17.8 17.6
a No significant differences were observed between prednisone and prednisolone, using Student's paired (test and Wilcoxon's sign rank test.
b Systemic availability is relative to an intravenous dose of prednisolone.
Abbreviations are P, oral prednisone; P0, oral prednisolone.
average prednisolone concentrations were 8 to 20 times the
corresponding prednisone levels after administration of either
oral steroid product. The half-life of prednisone averaged 4.6
0.9 hr (N = 4) and 4.8 0.5 hr (N = 4) following oral
prednisone and oral prednisolone, respectively.
Table I shows the results from total drug concentration
measurements. Peak prednisolone levels were found in the 0.5-
to 2-hr samples (except for patient 1 whose peak level occurred
at 3 hr after oral prednisolone) and were of similar magnitude
for each patient after either oral prednisone or oral predniso-
lone. Plasma prednisolone concentrations were readily measur-
able even in the blood samples obtained 15 mm after either drug
was administered. Thus, the conversion of prednisone to its
active metabolite prednisolone occurs very rapidly. There were
no significant differences in the mean half-life of plasma pred-
nisolone when comparing oral prednisone and oral predniso-
lone. Based on total drug plasma concentrations the average
bioavailability of prednisolone from oral prednisone and oral
prednisolone was 86,1 9.1% and 93.6 9.2%, respectively.
Figure 2 illustrates total plasma prednisolone concentrations in
patient 8 after the same dose of oral prednisone, oral predniso-
lone, and intravenous prednisolone. For the oral doses peak
levels occurred at the same time, and there is a close similarity
in plasma levels achieved. In this patient the bioavailability of
prednisolone was approximately 83% from oral prednisone and
93% from oral prednisolone.
Estimates of the protein binding parameters for prednisolone
determined from the intravenous doses, were CAP1, 167.87
52.04 ng/ml; KD1, 17.95 5.77 ng/ml and S, 2.06 0.88. The
bioavailability data for the two oral steroid preparations deter-
mined from unbound prednisolone concentrations are shown in
Table 1. The mean time of peak concentrations are the same as
seen with total drug concentration measurements. However,
with regard to peak concentrations there is a larger difference
between the two doses for some patients. For example, in
patients 5 and 6 the peak prednisolone concentration from the
oral prednisone is approximately 60% of that from oral prednis-
olone when based on unbound drug levels. In contrast, when
based upon total prednisolone concentrations the differences
between the two compounds is less; the peak concentration
from oral prednisone measuring 90% of that from oral predniso-
lone. The elimination half-life of prednisolone estimated from
unbound drug concentrations was very similar between the two
products, and mean values were not significantly different. The
absolute bioavailability of prednisolone estimated from un-
bound drug concentrations was not significantly different be-
tween the two formulations. Average values were 84.5 17.8%
and 95.5 17.6% for oral prednisone and oral prednisolone,
respectively. The mean values for each preparation determined
from unbound drug concentrations were very close to the mean
values based on total drug concentrations; however, the stan-
dard deviation was twice as great. In some cases, the actual
values for absolute bioavailability were quite different when
comparing estimates based on total or free drug concentrations.
For example, in patient 5 the prednisolone bioavailability from
oral prednisone measured 95% when total drug concentrations
were used and only 66% when free concentrations were used.
Furthermore, in this patient bioavailability is greater after oral
prednisone compared to oral prednisolone when total drug
measurements are used and the reverse is true when unbound
concentrations are used. Figure 3 shows the concentrations of
unbound prednisolone in patient eight. Peak concentrations
were higher after oral prednisolone and prednisolone availabil-
ity was 89% and 100% from oral prednisone and prednisolone,
respectively.
Comparison of prednisolone bioavailability between the
cushingoid and noncushingoid patients revealed no significant
differences between the two groups.
Table 2 lists the pharmacokinetic parameters of unbound
prednisolone following intravenous prednisolone in these pa-
tients. The mean systemic clearance of unbound drug was
approximately 12 ml/min'kg and the steady-state volume of
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1 11.0 10.8 2.1 2.0 5.4 2.4
2 8.8 8.8 1.8 1.8 3.6 2.7
3 11.2 11.0 2.0 1.9 7.8 2.4
4 10.8 10.0 2.0 1.8 4.9 2.4
5 14.1 13.9 2.2 2.2 5.2 2.1
6 9.3 9.1 1.8 1.7 4.7 2.3
7 10.8 10.6 2.2 2.2 3.4 2.5
8 14.7 14.5 2.8 2.7 11.1 2.5
9 14.2 13.9 3.1 3.1 5.1 2.8
Mean 11.7 11.4 2.2 2.2 5.7 2.5
SD 2.2 2.2 0.4 0.5 2.4 0.2
Abbreviations are CL, plasma clearance; Vss, volume of distribution
at steady-state; t'/2, a, initial disposition half-life; t'/2, 3, terminal
disposition half-life; 2CM, calculated using two-compartment model
equations; CI, calculated using compartment-independent equations.
distribution 2 liters/kg. The terminal half-life averaged 2.5hr,
similar to that seen from the oral prednisone and prednisolone
doses.
Only one patient (no. 1) had plasma concentrations of cortisol
higher than 10 ng/ml up to the first hour of blood sampling,
which was observed in both the oral and intravenous studies. In
the remainder of the patients cortisol concentrations were
unmeasurable.
Discussion
Prednisone and prednisolone products have been identified
as drugs with a potential for therapeutic inequivalence because
of bioavailability problems [24, 25]. This was suggested by poor
aqueous solubility and cases of therapeutic failure due to poor
absorption [26—28]. Although oral prednisone is used more
commonly than oral prednisolone, the two compounds are
generally believed to be therapeutically equivalent and inter-
changeable.
Early studies [4, 5] found that the oral administration of the
same dose of prednisone and prednisolone to normal subjects
resulted in similar prednisolone concentrations. Davis et al [6]
found peak prednisolone concentrations after a 10 mg oral dose
to normal subjects to be significantly higher following predniso-
lone than after prednisone being 115.8 22.8 ng/ml and 95.9
27.3 ng/ml, respectively. Areas under the plasma prednisolone-
time curve (AUC) were greater after prednisolone than after
prednisone although the difference was not significant owing to
the large scatter in AUC after prednisone. Prednisolone bio-
availability after prednisolone ranged from 22 to 127% (mean
78%) of that observed after prednisolone (determined as AUC
after prednisone/AUC after prednisolone). They [6] concluded
that if predictable plasma prednisolone concentrations are to be
achieved, prednisolone should be used rather than prednisone.
Tse and Welling [7] studied a single healthy subject after the
same oral dose of prednisolone and prednisone and observed
plasma prednisolone profiles to be similar after each drug but
much higher during the first 4 hr after prednisolone. The
Fig. 3. Unbound plasma prednisolone concentrations in patient 8
following the administration of 22 .5 mg of intravenous prednisolone,( ), oral prednisolone, (O ), and oral pred-
nisone (0 0).
prednisolone AUC following oral prednisone was 75% of that
after oral prednisolone.
Meikle, Weed, and Tyler [8] administered oral prednisone
and an equivalent dose of intravenous prednisolone to normal
subjects and determined that 69 12% of oral prednisone was
absorbed and metabolized to prednisolone. Subsequently Peter-
eit and Meikle [9] administered prednisolone orally and intrave-
nously to normals and found the bioavailability of prednisolone
higher than in their study with oral prednisone being 82 13%
with a range of 60 to 92%.
The purpose of our study was to compare in kidney trans-
plant patients the bioavailability of prednisolone from oral
prednisone and oral prednisolone relative to an intravenous
dose of prednisolone. In addition, we were able to estimate
prednisolone bioavailability using both total and unbound drug
concentrations. Because the binding of prednisolone changes
with concentration, estimates of clearance based on total drug
concentrations are misleading because they are confounded by
the variation in binding. We believe that using unbound drug
concentrations are more appropriate for prednisolone bioavail-
ability studies. During the intravenous studies where the high-
est plasma concentrations are obtained, the unbound fraction
averaged 28% at the highest concentrations and declined to 9%
at the lowest concentrations. In a study of healthy subjects by
Rose, Yurchak, and Jusko [3] clearance (Dose/AUC), as well as
steady-state volume of distribution based on unbound drug
concentrations exhibited no significant differences in relation to
dose after 5, 20, and 40mg of prednisolone given intravenously.
However, when these pharmacokinetic parameters were deter-
mined from total drug concentrations, significant increases
occurred with increasing dose. Because one of the basic as-
sumptions in the calculation of bioavailability is that clearance
remains constant [29], the use of unbound drug concentrations
appear to be the most suitable.
An interesting finding was the larger intersubject variability
in unbound drug bioavailability compared to that based on total
300
4 6 8 10 12
Time, hr
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prednisolone concentrations (Table 1). The reason for this is
unknown; however, it has been observed previously [181.
Estimates of the pharmacokinetic parameters for unbound
prednisolone in our patients (Table 2) were similar to those
observed in healthy subjects administered 5, 20, and 40 mg of
intravenous prednisolone [3]. Mean values for unbound drug
were reported to range from 828 to 1050 ml/min/l.73 m2 for
plasma clearance; 117 to 168 liters/l.73 m2 for steady-state
volume of distribution; and 1.7 to 2.2 hr for half-life. The
estimation of prednisolone half-life based on unbound drug
concentrations is shorter than that observed from total drug
concentrations due to the non-linear plasma protein binding [30,
311.
In conclusion, no significant differences were observed in
mean values between the two oral formulations tested whether
based on total or unbound drug concentrations. However, it is
important to note that seven of nine patients had greater
absolute systemic bioavailability (range 6 to 30%) of predniso-
lone from prednisolone tablets using unbound drug data. Obvi-
ously, the results of any study of this type are somewhat
dependent on the commercial preparation being utilized and
specific formulation factors which might affect bioavailability.
The results of our study indicate that both of the oral prepara-
tions tested, prednisone and prednisolone, provide similar
bloavailability of active prednisolone. Furthermore, the conver-
sion of prednisone to prednisolone occurs rapidly in these
patients. Thus kidney transplant patients should obtain approxi-
mately the same effect and be able to receive either oral
corticosteroid for immunosuppressive therapy.
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